Straits Times Index
3,303.26 -10.79 (-0.33%) S&P 500
5,308.13 +4.86 (+0.09%) Dow
39,806.77 -196.82 (-0.49%) Nasdaq
16,794.88 +108.91 (+0.65%) Bitcoin USD
71,011.23 +4,055.40 (+6.06%) CMC Crypto 200
1,527.35 +38.81 (+2.61%)
Biohaven Ltd. (BHVN)
Pre-market:
| Previous close | 37.37 |
| Open | 37.26 |
| Bid | 0.00 x 800 |
| Ask | 43.00 x 800 |
| Day's range | 37.21 - 40.13 |
| 52-week range | 14.96 - 62.21 |
| Volume | |
| Avg. volume | 1,408,991 |
| Market cap | 3.472B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.
- PR Newswire
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the closing of its underwritten public offering of 6,451,220 of its common shares, which includes the full exercise of the underwriters' option to purchase 841,463 additional common shares, at a public offering price of $41.00 per share. The gross proceeds from t
- PR Newswire
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public
